Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

被引：87

作者：

Grande, Enrique ^{[1
]}

Bolos, Maria-Victoria ^{[2
]}

Arriola, Edurne ^{[3
]}

机构：

[1] Ramon y Cajal Univ Hosp, Med Oncol Serv, Gastrointestinal & Early Drug Dev Unit, Madrid, Spain

[2] Pfizer Oncol, Madrid, Spain

[3] Hosp del Mar, Dept Oncol, Barcelona, Spain

来源：

MOLECULAR CANCER THERAPEUTICS | 2011年 / 10卷 / 04期

关键词：

ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; EML4-ALK FUSION GENE; SMALL-MOLECULE INHIBITOR; LUNG-CANCER; TYROSINE KINASE; GROWTH-FACTOR; PERSONALIZED MEDICINE; ACTIVATING MUTATIONS; EXPERIMENTAL-MODELS;

D O I：

10.1158/1535-7163.MCT-10-0615

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK. Mol Cancer Ther; 10(4); 569-79. (C) 2011 AACR.

引用

页码：569 / 579

页数：11

共 95 条

[1] A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation [J].

Adam, P ;

Katzenberger, T ;

Seeberger, H ;

Gattenlöhner, S ;

Wolf, J ;

Steinlein, C ;

Schmid, M ;

Müller-Hermelink, HK ;

Ott, G .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (11) :1473-1476

[2] p130Cas mediates the transforming properties of the anaplastic lymphoma kinase [J].

Ambrogio, C ;

Voena, C ;

Manazza, AD ;

Piva, R ;

Riera, L ;

Barberis, L ;

Costa, C ;

Tarone, G ;

Defilippi, P ;

Hirsch, E ;

Erba, EB ;

Mohammed, S ;

Jensen, ON ;

Palestro, G ;

Inghirami, G ;

Chiarle, R .

BLOOD, 2005, 106 (12) :3907-3916

[3] NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells [J].

Ambrogio, Chiara ;

Martinengo, Cinzia ;

Voena, Claudia ;

Tondat, Fabrizio ;

Riera, Ludovica ;

di Celle, Paola Francia ;

Inghirami, Giorgio ;

Chiarle, Roberto .

CANCER RESEARCH, 2009, 69 (22) :8611-8619

[4]

[Anonymous], 2009, MOL CANC THER

[5] TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins [J].

Armstrong, Florence ;

Lamant, Laurence ;

Hieblot, Corinne ;

Delsol, Georges ;

Touriol, Christian .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) :640-646

[6] Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity [J].

Bai, RY ;

Dieter, P ;

Peschel, C ;

Morris, SW ;

Duyster, J .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :6951-6961

[7] Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway [J].

Bai, RY ;

Tao, OY ;

Miething, C ;

Morris, SW ;

Peschel, C ;

Duyster, J .

BLOOD, 2000, 96 (13) :4319-4327

[8] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [J].

Bang, Y. ;

Kwak, E. L. ;

Shaw, A. T. ;

Camidge, D. R. ;

Iafrate, A. J. ;

Maki, R. G. ;

Solomon, B. J. ;

Ou, S. I. ;

Salgia, R. ;

Clark, J. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[9] NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry [J].

Bassermann, F ;

von Klitzing, C ;

Münch, S ;

Bai, RY ;

Kawaguchi, H ;

Morris, SW ;

Peschel, C ;

Duyster, J .

CELL, 2005, 122 (01) :45-57

[10] Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications [J].

Bilsland, James G. ;

Wheeldon, Alan ;

Mead, Andrew ;

Znamenskiy, Petr ;

Almond, Sarah ;

Waters, Kerry A. ;

Thakur, Matthew ;

Beaumont, Vahri ;

Bonnert, Timothy P. ;

Heavens, Robert ;

Whiting, Paul ;

McAllister, George ;

Munoz-Sanjuan, Ignacio .

NEUROPSYCHOPHARMACOLOGY, 2008, 33 (03) :685-700

← 1 2 3 4 5 6 7 8 9 10 →